Lineage Cell Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LCTX research report →
About the company
Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
- CEO
- Brian Culley
- IPO
- 1992
- Employees
- 75
- HQ
- Carlsbad, CA, US
Price Chart
- Market Cap
- $336.55M
- P/E
- -4.89
- P/S
- 22.77
- P/B
- 6.14
- EV/EBITDA
- -7.02
- Div Yield
- 0.00%
- Gross Margin
- 97.98%
- Op Margin
- -255.14%
- Net Margin
- -434.44%
- ROE
- -152.10%
- ROIC
- -34.07%
- Revenue
- $14.56M · 53.24%
- Net Income
- $-63,533,000 · -241.41%
- EPS
- $-0.28 · -201.08%
- Op Income
- $-21,779,000
- FCF YoY
- 17.82%
- 52W High
- $2.09
- 52W Low
- $0.93
- 50D MA
- $1.32
- 200D MA
- $1.60
- Beta
- 1.51
- Avg Volume
- 1.54M
Get TickerSpark's AI analysis on LCTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Bradsher Neal C | other | 125,000 |
| Jul 1, 26 | Jayasuriya Anula | other | 125,000 |
| Jul 1, 26 | Mulroy Michael H. | other | 125,000 |
| Jul 1, 26 | ANDREWS DEBORAH J | other | 125,000 |
| Jul 1, 26 | Russell Angus C. | other | 125,000 |
| Jul 1, 26 | Amin Dipti | other | 125,000 |
| Mar 12, 26 | Culley Brian M | buy | 15,000 |
| Mar 5, 26 | Culley Brian M | other | 3,250,000 |
| Mar 5, 26 | Howe Jill Ann | other | 1,050,000 |
| Mar 5, 26 | Samuel George A. III | other | 900,000 |
Our LCTX coverage
Recent articles, reports, and earnings notes.
No research on LCTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LCTX report →Similar companies
Peers in the same neighborhood.